Gufic Biosciences Ltd
GUFICBIO
Company Profile
Business description
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral and a proton-pump inhibitor. It derives maximum revenue from India.
Contact
SM House, 11 Sahakar Road
1st to 4th Floor
Vile Parle (East)
MumbaiMH400 057
INDT: +91 2267261000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
2,671
Stocks News & Analysis
stocks
3 cheap ASX stocks owned by top rated funds
Our analysts think these companies are undervalued and their shares appear to have the stamp of approval from highly rated managers.
stocks
Chart of the week: Why small caps could shine bright in 2025
The Chart of the Week is a reason why small caps may shine bright in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,611.50 | 9.80 | 0.11% |
| CAC 40 | 8,122.58 | 12.04 | 0.15% |
| DAX 40 | 22,314.65 | 118.98 | -0.53% |
| Dow JONES (US) | 44,176.65 | 450.94 | -1.01% |
| FTSE 100 | 8,662.97 | 49.56 | -0.57% |
| HKSE | 22,576.98 | 367.26 | -1.60% |
| NASDAQ | 19,962.36 | 93.89 | -0.47% |
| Nikkei 225 | 38,678.04 | 486.57 | -1.24% |
| NZX 50 Index | 12,784.88 | 95.48 | -0.74% |
| S&P 500 | 6,117.52 | 26.63 | -0.43% |
| S&P/ASX 200 | 8,338.20 | 15.40 | 0.19% |
| SSE Composite Index | 3,350.78 | 0.76 | -0.02% |